Literature DB >> 20333493

Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery.

Thomas Wilke1, Jörn Moock, Sabrina Müller, Matthias Pfannkuche, Andreas Kurth.   

Abstract

BACKGROUND: According to some current guidelines, extended thromboprophylaxis after hip and knee arthroplasties is recommended. Outpatient prophylaxis with low molecular weight heparins (LMWH) is an important part of this prophylaxis, although the rates of adherence to these regimens is not known. QUESTIONS/PURPOSES: We determined (1) the degree of nonadherence (NA) of patients with LMWH outpatient prophylaxis, and (2) whether specific independent factors explain NA.
METHODS: NA was determined by syringe count and by indirect and direct questions to patients. We defined six different NA indicators. To identify factors explaining LMWH NA, we used three different logistic regression models.
RESULTS: NA rates ranged between 13% and 21% depending on the indicator used for measurement. Patients who were nonadherent missed between 38% and 53% of their outpatient LMWH injections. If patients attended an outpatient rehabilitation program, the probability for their NA increased substantially. Moreover, the NA probability increased with each additional day between acute hospitalization and start of rehabilitation (linking days). NA was lower for patients who feared thrombosis or who believed antithrombotic drugs to be the most important measure in thromboprophylaxis. LEVEL OF EVIDENCE: Level II, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20333493      PMCID: PMC2919876          DOI: 10.1007/s11999-010-1306-8

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  51 in total

1.  The brief illness perception questionnaire.

Authors:  Elizabeth Broadbent; Keith J Petrie; Jodie Main; John Weinman
Journal:  J Psychosom Res       Date:  2006-06       Impact factor: 3.006

2.  Why illness perceptions matter.

Authors:  Keith J Petrie; John Weinman
Journal:  Clin Med (Lond)       Date:  2006 Nov-Dec       Impact factor: 2.659

Review 3.  Medication adherence and persistence: a comprehensive review.

Authors:  Kem P Krueger; Bruce A Berger; Bill Felkey
Journal:  Adv Ther       Date:  2005 Jul-Aug       Impact factor: 3.845

4.  How often is medication taken as prescribed? A novel assessment technique.

Authors:  J A Cramer; R H Mattson; M L Prevey; R D Scheyer; V L Ouellette
Journal:  JAMA       Date:  1989-06-09       Impact factor: 56.272

5.  Development and validation of an immunosuppressant therapy adherence barrier instrument.

Authors:  Marie A Chisholm; Charles E Lance; Gail M Williamson; Laura L Mulloy
Journal:  Nephrol Dial Transplant       Date:  2004-11-30       Impact factor: 5.992

6.  Patients' self-reported adherence to cardiovascular medication using electronic monitors as comparators.

Authors:  Andreas Zeller; Esther Ramseier; Anne Teagtmeyer; Edouard Battegay
Journal:  Hypertens Res       Date:  2008-11       Impact factor: 3.872

7.  Comparison of methods to assess medication adherence and classify nonadherence.

Authors:  Richard A Hansen; Mimi M Kim; Liping Song; Wanzhu Tu; Jingwei Wu; Michael D Murray
Journal:  Ann Pharmacother       Date:  2009-03-03       Impact factor: 3.154

8.  Can simple clinical measurements detect patient noncompliance?

Authors:  R B Haynes; D W Taylor; D L Sackett; E S Gibson; C D Bernholz; J Mukherjee
Journal:  Hypertension       Date:  1980 Nov-Dec       Impact factor: 10.190

9.  Patient education about anticoagulant medication: is narrative evidence or statistical evidence more effective?

Authors:  Kathleen M Mazor; Joann Baril; Elizabeth Dugan; Frederick Spencer; Pamela Burgwinkle; Jerry H Gurwitz
Journal:  Patient Educ Couns       Date:  2007-10-17

10.  Development of the ASK-20 adherence barrier survey.

Authors:  Steven R Hahn; Jinhee Park; Elizabeth P Skinner; Kristina S Yu-Isenberg; Mary B Weaver; Bruce Crawford; Peggy W Flowers
Journal:  Curr Med Res Opin       Date:  2008-06-12       Impact factor: 2.580

View more
  16 in total

1.  Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures.

Authors:  Anhua Long; Lihai Zhang; Yingze Zhang; Baoguo Jiang; Zhi Mao; Hongda Li; Shanbao Zhang; Zongyan Xie; Peifu Tang
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

2.  [Patient pathways in thrombosis prophylaxis after hip and knee replacement surgery : results of a survey].

Authors:  S Müller; T Wilke; M Pfannkuche; I Meber; A Kurth; H Merk; F Steinfeldt; D Ganzer; C Perka
Journal:  Orthopade       Date:  2011-07       Impact factor: 1.087

3.  Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?

Authors:  Abiram Bala; James I Huddleston; Stuart B Goodman; William J Maloney; Derek F Amanatullah
Journal:  Clin Orthop Relat Res       Date:  2017-05-31       Impact factor: 4.176

4.  Continuation of venous thromboembolism prophylaxis after hospital discharge into the outpatient setting: the ACCEPT study.

Authors:  Sebastian M Schellong; Jürgen Kaiser; Peter Bramlage
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

5.  Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial.

Authors:  Sebastian Werth; Rupert Bauersachs; Horst Gerlach; Eberhard Rabe; Sebastian Schellong; Jan Beyer-Westendorf
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

6.  Patient Adherence and Experience with Extended Use of Prophylactic Low-Molecular-Weight Heparin Following Pancreas and Liver Resection.

Authors:  Madeline Lemke; Kaitlyn Beyfuss; Julie Hallet; Natalie G Coburn; Calvin H L Law; Paul J Karanicolas
Journal:  J Gastrointest Surg       Date:  2016-09-29       Impact factor: 3.452

7.  Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer.

Authors:  M Farzan Rashid; Terri L Jackson; Jheanell A Morgan; Franklin A Dwyer; Beth A Schrope; John A Chabot; Michael D Kluger
Journal:  J Gastrointest Surg       Date:  2018-09-05       Impact factor: 3.452

8.  Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery.

Authors:  Sebastian Werth; Kai Halbritter; Jan Beyer-Westendorf
Journal:  Ther Clin Risk Manag       Date:  2012-03-23       Impact factor: 2.423

Review 9.  Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.

Authors:  Christina L Fanola
Journal:  Vasc Health Risk Manag       Date:  2015-05-27

10.  Validation of the Adherence Barriers Questionnaire - an instrument for identifying potential risk factors associated with medication-related non-adherence.

Authors:  Sabrina Müller; Thomas Kohlmann; Thomas Wilke
Journal:  BMC Health Serv Res       Date:  2015-04-10       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.